CN118139894A - 抗pla2g2d构建体及其用途 - Google Patents

抗pla2g2d构建体及其用途 Download PDF

Info

Publication number
CN118139894A
CN118139894A CN202280066768.1A CN202280066768A CN118139894A CN 118139894 A CN118139894 A CN 118139894A CN 202280066768 A CN202280066768 A CN 202280066768A CN 118139894 A CN118139894 A CN 118139894A
Authority
CN
China
Prior art keywords
amino acid
seq
acid sequence
cdr1
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280066768.1A
Other languages
English (en)
Chinese (zh)
Inventor
L-F·李
K·卢
J·于
J·黄
M·吴
A·Y·陈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Immune Biotechnology Co
Original Assignee
Advanced Immune Biotechnology Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Immune Biotechnology Co filed Critical Advanced Immune Biotechnology Co
Priority claimed from PCT/US2022/074496 external-priority patent/WO2023015225A1/en
Publication of CN118139894A publication Critical patent/CN118139894A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01004—Phospholipase A2 (3.1.1.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202280066768.1A 2021-08-04 2022-08-03 抗pla2g2d构建体及其用途 Pending CN118139894A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163229437P 2021-08-04 2021-08-04
US63/229,437 2021-08-04
PCT/US2022/074496 WO2023015225A1 (en) 2021-08-04 2022-08-03 Anti-pla2g2d constructs and uses thereof

Publications (1)

Publication Number Publication Date
CN118139894A true CN118139894A (zh) 2024-06-04

Family

ID=85128598

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280066768.1A Pending CN118139894A (zh) 2021-08-04 2022-08-03 抗pla2g2d构建体及其用途

Country Status (6)

Country Link
US (1) US20240327540A1 (https=)
EP (1) EP4380690A4 (https=)
JP (1) JP2024528987A (https=)
CN (1) CN118139894A (https=)
AU (1) AU2022323177A1 (https=)
CA (1) CA3178008A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021155305A1 (en) * 2020-01-30 2021-08-05 Apeximmune Therapeutics Inc. Methods and compositions for treating cancer or viral infection with a pla2g2d antagonist

Also Published As

Publication number Publication date
CA3178008A1 (en) 2023-02-04
JP2024528987A (ja) 2024-08-01
EP4380690A4 (en) 2025-02-26
AU2022323177A1 (en) 2024-03-07
US20240327540A1 (en) 2024-10-03
EP4380690A1 (en) 2024-06-12

Similar Documents

Publication Publication Date Title
TWI825431B (zh) FcRH5之人源化及親和力成熟抗體及使用方法
JP7702961B6 (ja) 抗ｃｄ１３７コンストラクト、多重特異性抗体及びその使用
JP7818570B2 (ja) 抗ｃｄ９３構築物およびその使用
WO2022067262A1 (en) Anti-cd93 constructs and uses thereof
US20230112085A1 (en) Anti-b7-h4 constructs and uses thereof
WO2021247769A1 (en) Anti-cd93 constructs and uses thereof
JP7791826B2 (ja) 抗ｃｄ１３７コンストラクト、多重特異性抗体及びその使用
JP7715722B2 (ja) 抗ｃｄ１３７コンストラクト及びその使用
CN118139894A (zh) 抗pla2g2d构建体及其用途
WO2021164701A1 (en) Fusion proteins and uses thereof
TW202302646A (zh) 抗vista構築體及其用途
US20240425588A1 (en) Anti-tigit constructs and uses thereof
WO2023015225A1 (en) Anti-pla2g2d constructs and uses thereof
CN121568958A (zh) 抗SIRPα抗体及其用途
US20260078185A1 (en) Anti-vista constructs and uses thereof
TWI917387B (zh) 抗ｃｄ９３之構築體及其用途
WO2025259563A2 (en) Anti-cd3 constructs and uses thereof
HK40126939A (zh) 抗vista构建体及其用途
HK40079270A (en) Anti-cd137 construct and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination